Table of Contents
PPT Slide
Criteria for Developing the Priority List
Rule vs FDAMA
Additional Factors
Development of the Priority List: Off-patent Therapies
Development of the Priority List: Off-patent Therapies
Development of the Priority List: Off-patent Therapies
Review of “Preliminary” Priority List*: Cardiorenal
Review of “Preliminary” Priority List*: Neuropharm
Review of “Preliminary” Priority List*: Pulmonary
Review of “Preliminary” Priority List: Antimicrobials
Review of “Preliminary” Priority List*: GI
|